


IN THE CLAIMS

1. (original) A compound of formula (I) or pharmaceutically acceptable salts, solvates or polymorphs thereof;



wherein;

X is S or CH₂;

L and U, which may be the same or different, are -N-, -N⁺(-O⁻)- or -C(H)-;

M and Q, which may be the same or different, are -N-, -N⁺(-O⁻)- or -C(R⁴)-;

wherein ring A contains 1 or 2 nitrogen atoms, and wherein when L, U, M or Q is -N⁺(-O⁻)-, ring A contains no other nitrogen atom;

R¹ and R², which may be the same or different, are hydrogen, C₁-C₆alkyl, (CH₂)_m(C₃-C₆cycloalkyl) wherein m = 0, 1, 2 or 3, or R¹ and R² together with the nitrogen to which they are attached form an azetidine ring;

W, Y and Z, which may be the same or different, are hydrogen, halogen, C₁-C₆alkyl, CF₃, OCF₃, C₁-C₄alkylthio or C₁-C₄alkoxy; or Y and Z are linked so that, together with the interconnecting atoms, Y and Z form a fused 5 to 7-membered carbocyclic or heterocyclic ring which may be saturated, unsaturated or aromatic, and wherein when Y and Z form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; and wherein W, Y and Z are not all hydrogen;

and

each R⁴ is independently:

$-(CH_2)_p-R^5$;

where p is 0, 1 or 2;

R^5 is hydrogen, $CONR^6R^7$, $SO_2NR^6R^7$, $SO_2NHC(=O)R^6$, hydroxy,

C_1 - C_4 alkoxy, $NR^8SO_2R^9$, NO_2 , NR^6R^{11} , CN , CO_2R^{10} , SR^{10} , $S(O)R^9$ or SO_2R^{10} ; R^6 , R^7 , R^8 and R^{10} which may be the same or different, are hydrogen or C_1 - C_6 alkyl optionally substituted independently by one or more R^{12} ; R^9 is C_1 - C_6 alkyl optionally substituted independently by one or more R^{12} ; R^{11} is hydrogen, C_1 - C_6 alkyl optionally substituted independently by one or more R^{12} , $C(O)R^6$, CO_2R^9 , $C(O)NHR^6$ or $SO_2NR^6R^7$; R^{12} is fluoro, hydroxy, CO_2H , C_3 - C_6 cycloalkyl, NH_2 , $CONH_2$, C_1 - C_6 alkoxy, C_1 - C_6 alkoxycarbonyl or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O optionally substituted independently by one or more R^{13} ; or R^6 and R^7 , together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring optionally substituted independently by one or more R^{13} ; or

a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R^{13} ;

wherein R^{13} is hydroxy, C_1 - C_4 alkoxy, fluoro, C_1 - C_6 alkyl, haloalkyl, haloalkoxy, $-NH_2$, $-NH(C_1-C_6alkyl)$ or $-N(C_1-C_6alkyl)_2$; or

when both M and Q are CR^4 , the R^4 groups are linked so that together with the interconnecting atoms, the R^4 groups form a fused 5- to 7-membered carbocyclic or heterocyclic ring which may be saturated, unsaturated or aromatic.

2. (original) A compound according to claim 1 wherein L and U are $-CH-$.
3. (original) A compound according to any preceding claim wherein W, Y and Z are each independently selected from hydrogen, methyl, ethyl, CF_3 , OCF_3 , C_1 - C_4 alkylthio, methoxy, ethoxy, chloro, fluoro and bromo.
4. (original) A compound according to claim 3 wherein W and Z are hydrogen.

5. (currently amended) A compound according to ~~any preceding~~ claim 4 wherein Y is methylthio.
6. (currently amended) A compound according to ~~any preceding~~ claim 5 wherein M and Q are each independently selected from -N- and -CH-.
7. (currently amended) A compound according to ~~any preceding~~ claim 6 wherein R¹ and R² are each independently selected from hydrogen and C₁-C₆alkyl.
8. (original) A compound according to claim 6 wherein R¹ is methyl and R² is hydrogen or methyl.
9. (original) A compound according to claim 1 wherein the compound is selected from:

N-methyl-*N*-[(4-{[4-(methylsulfanyl)phenyl]sulfanyl}-3-pyridinyl)methyl]amine,
N,N-dimethyl-*N*-[(4-{[4-(methylsulfanyl)phenyl]sulfanyl}-3-pyridinyl)methyl]amine,
N-methyl-*N*-[(3-{[4-(methylsulfanyl)phenyl]sulfanyl}-4-pyridinyl)methyl]amine,
N,N-dimethyl-*N*-[(3-{[4-(methylsulfanyl)phenyl]sulfanyl}-4-pyridinyl)methyl]amine,
N-methyl-*N*-[(3-[4-(methylsulfanyl)benzyl]-4-pyridinyl)methyl]amine,
N,N-dimethyl-*N*-[(3-[4-(methylsulfanyl)benzyl]-4-pyridinyl)methyl]amine,
N-methyl-*N*-[(4-[4-(methylsulfanyl)benzyl]-3-pyridinyl)methyl]amine, and
N,N-dimethyl-*N*-[(4-[4-(methylsulfanyl)benzyl]-3-pyridinyl)methyl]amine,
 or pharmaceutically acceptable salts, solvates or polymorphs thereof.

10. (currently amended) A composition comprising a compound of claim 1 ~~formula (I) as claimed in any one of the preceding claims,~~ or pharmaceutically acceptable salts, solvates or polymorphs thereof, and a pharmaceutically acceptable diluent or carrier.

11. (cancelled) ~~A compound of formula (I) as claimed in any one of the preceeding claims, or pharmaceutically acceptable salts, solvates or polymorphs thereof, for use as a medicament.~~
12. (currently amended) A method of treating ~~The use of a compound of formula (I) as claimed in any one of the preceeding claims, or pharmaceutically acceptable salts, solvates or polymorphs thereof, in the preparation of a medicament for the treatment or prevention of a disorder in which the regulation of monoamine transporter function is implicated by~~ administering a compound of claim 1.
13. (Currently amended) A method Use according to claim 12 wherein the disorder is selected from hypertension, depression, generalized anxiety disorder, phobias, post-traumatic stress syndrome, avoidant personality disorder, sexual dysfunction (including premature ejaculation and male impotence), eating disorders, obesity, substance abuse disorders (including chemical dependencies), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania, headache (associated with vascular disorders), emotional lability, pathological crying, sleeping disorder (cataplexy) and shock.
14. (Currently amended) A method Use according to claim 13 wherein the disorder is selected from depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, substance abuse disorders and sexual dysfunction (including premature ejaculation and male impotence).
15. (Currently amended) A method Use according to claim 14 wherein the disorder is premature ejaculation.